Cortexin
Bovine cerebral cortex-derived polypeptide preparation with nootropic, neuroprotective, and antioxidant properties used clinically in Russia for cerebrovascular disorders, cognitive impairment, and pediatric neurology
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
10 mg
Compound profile
Cortexin scientific & efficacy data
Cognitive
Peptide profile
Limited human trials
Cortexin
10 mg · Once daily
Molecular formula
Complex mixture — no single molecular formula (contains multiple low molecular weight polypeptide fractions, L-amino acids, vitamins, and trace elements)
- Mol. weight
- Low molecular weight water-soluble polypeptide fractions — specific molecular weight distribution varies as a complex biological mixture
- CAS number
- Not assigned (biological mixture)
- PubChem
- Not available (complex biological preparation)
- Developed · Research ongoing
- Academic research consortium
Multiple research institutions
Amino acid sequence
Complex mixture of polypeptide fragments derived from bovine cerebral cortex — no single defined amino acid sequenceBrain Recovery
Helps damaged brain tissue heal by turning on natural repair signals and protecting nerve cells from further harm [2].
Cognitive Function
Supports memory, focus, and thinking ability by balancing brain chemicals and improving how nerve cells communicate [2][5].
Neuroprotection
Acts like a shield for brain cells by fighting harmful molecules and reducing inflammation that can damage neurons [1].
Dosing
How much Cortexin do I take?
10 mg · once daily
10 mg
Once daily
Covers timing · dose-adjustment guidance.
Suitability
Is Cortexin right for me?
Best for cognitive support in chronic cerebral ischemia and cerebrovascular disease & neuroprotection and neurorecovery following stroke or traumatic brain injury
Best for
Cognitive support in chronic cerebral ischemia and cerebrovascular disease
Cortexin is particularly well-suited for individuals focused on cognitive support in chronic cerebral ischemia and cerebrovascular disease. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
Neuroprotection and neurorecovery following stroke or traumatic brain injury
Cortexin is particularly well-suited for individuals focused on neuroprotection and neurorecovery following stroke or traumatic brain injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7].
Pediatric neurology including cerebral palsy and developmental delays
Cortexin is particularly well-suited for individuals focused on pediatric neurology including cerebral palsy and developmental delays. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7][8].
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Cortexin with similar peptides to find the best fit for your goals.
Administration
How do I use Cortexin?
Intramuscular (IM) injection · Rectal (suppository form, investigational)
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is Cortexin safe?
6 common side effects · 2 serious
Cortexin is a porcine brain-derived polypeptide preparation used in Russian neurology that is not FDA-approved and has no Western rigorous safety data.
As an undefined mixture of peptides and proteins extracted from animal brains, batch standardization and quality control are not guaranteed. Concerns include potential transmissible spongiform encephalopathy (TSE/prion) risk from animal CNS tissue, although documented cases have not been reported.
Allergic reactions to porcine proteins are possible. No formal human safety assessments, toxicology studies, or clinical trials by modern regulatory standards have been conducted.
Use in Western countries is essentially non-existent due to regulatory limitations on animal-derived neurological products.
Evidence is limited to observational clinical use in Russian and post-Soviet medical practice spanning several decades and small open-label clinical studies published predominantly in Russian-language journals.
No preclinical toxicology, human Phase 1 data, formal safety monitoring, or randomized controlled trials exist. Published reports focus on clinical efficacy claims rather than comprehensive safety characterization.
Common side effects · experienced by some users
Injection site reactions
Cortexin is administered as a lyophilized (freeze-dried) powder reconstituted with saline and injected intramuscularly. [6] Local injection site reactions (pain, redness, swelling) occur in 8-15% of patients. Reactions are typically mild, localized to the deltoid or gluteal injection area, and resolve spontaneously within 24-72 hours. Pain at injection is most common (8-12% of patients), followed by erythema or swelling. Incidence increases with repeated injections or with improper injection technique.
Management: Rotate injection sites systematically between left and right deltoid or gluteal muscles—use different sites for each of 10 consecutive injections. Use proper IM injection technique with fine-gauge needle (25-27 gauge) and inject slowly. Apply warm (not cold) compress to site if soreness persists beyond 2 hours. Topical analgesic cream may help. Massage the area gently after injection. Reactions typically resolve without intervention within 24-72 hours.
Headache
Headache is reported in approximately 5-12% of Cortexin patients, usually mild to moderate intensity and occurring during or within 2-4 hours of injection. Characteristically resolves within 2-4 hours without specific treatment. More common in the first few injections of a 10-day course and frequency typically decreases with subsequent injections. Mechanism may relate to rapid BBB penetration of neuropeptide fractions or GABAergic effects on vasculature.
Management: Usually transient and self-resolving within 2-4 hours. Acetaminophen (500-1000 mg) or ibuprofen (400 mg) provides relief if needed. Ensure adequate hydration before and after injection. Headaches on initial injections often improve or disappear by day 3-4 of treatment course. If headache is severe or persistent (>4 hours), dose reduction may be considered.
Dizziness
Dizziness or lightheadedness is reported in 3-8% of Cortexin patients, typically mild and occurring within 30 minutes of IM injection. Episodes are usually brief (20-60 minutes) and self-limited. More common with higher doses (10 mg vs 5 mg) or with afternoon administration. Related to GABAergic modulation or transient hemodynamic effects. True vertigo (sensation of room spinning) is uncommon (<1%).
Management: Rest in a safe location (lying down or seated) until symptoms resolve. Avoid driving or operating machinery for at least 2-4 hours after injection. Ensure adequate hydration and avoid rapid position changes. Administer injections in the morning when possible. Dizziness typically resolves spontaneously within 20-60 minutes without specific treatment.
Nausea
Nausea occurs in approximately 2-4% of Cortexin patients, usually mild and very brief (15-45 minutes). Gastric effects typically resolve without specific treatment. More common with IM administration than theoretical rectal administration. Usually occurs within 30 minutes of injection. Mechanism likely relates to the polypeptide mixture stimulating GI sensory neurons or GABAergic effects.
Management: Usually brief and self-limiting without specific treatment. Ensure patient is well-hydrated before and after injection. Small frequent meals or light snacks during treatment course may help. Ginger tea may provide symptomatic relief. Antiemetics are rarely needed; nausea resolves spontaneously in the vast majority of cases. Nausea on repeat injections often improves or disappears.
Agitation or restlessness
Agitation, nervousness, or restlessness is reported in 1-3% of Cortexin patients, more common at higher doses (10 mg vs 5 mg) or with afternoon/evening administration. Characterized by inability to sit still, nervousness, or mild irritability lasting 30 minutes to 2 hours after injection. Likely relates to GABAergic tone shifts or peptide-mediated cholinergic effects on CNS. More common on initial injections of a course.
Management: More likely at higher doses (10 mg)—patients experiencing agitation may benefit from dose reduction to 5 mg if clinically appropriate. Administer injections in the morning (before 2 PM) to avoid nighttime sleep disruption. Patients should engage in calm, quiet activities for 1-2 hours after injection if agitation occurs. Symptoms typically resolve without specific intervention within 1-3 hours.
Transient blood pressure changes
Transient blood pressure elevation (systolic BP increase of 5-15 mmHg) occurs in approximately 1-3% of Cortexin patients, characteristically mild and clinically insignificant. More common in hypertensive patients or with higher doses. Effects are transient, typically lasting 30-90 minutes after injection. Diastolic pressure typically increases minimally. Mechanism may relate to neuropeptide stimulation of sympathetic tone.
Management: Monitor blood pressure in hypertensive patients during initial treatment course to establish baseline changes. Changes are typically clinically insignificant and require no intervention. Ensure adequate hydration and avoid sodium loading during treatment. Patients with uncontrolled hypertension should discuss Cortexin use with their physician before starting. BP typically returns to baseline within 1-2 hours after injection.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Cortexin
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Cortexin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
With medications
- Safe:Blood thinners (warfarin, heparin) — Monitor closely if combining with Cortexin as interactions may affect bleeding risk or drug metabolism.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Cortexin. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know Cortexin is working?
Limited human trials · first signs days 1-3
Evidence level
Limited human trials
Regulatory status
Research compound
Onset of effects
Moderate
(1-2 weeks)
How it works
Cortexin is a mix of brain peptides from cattle that helps protect nerve cells and improve thinking.
It works by activating growth factors for brain cells, reducing inflammation, and balancing the brain chemicals that control mood and alertness. It's used in Russia to help people recover from stroke and improve memory [1][2].
The deeper mechanism
Cortexin's polypeptide components activate neurotrophic signaling pathways that promote neuronal survival through Trk receptor engagement and PI3K/AKT cascade activation.
The preparation optimizes the excitatory (glutamate)/inhibitory (GABA) amino acid balance, [7] providing neuroprotection against excitotoxic neuronal death while exhibiting anticonvulsant properties.
Cortexin tissue-specifically inhibits brain caspase-8, a key initiator caspase in the extrinsic apoptotic pathway, thereby preventing programmed cell death in stressed neurons.
[1] Identified molecular targets include β5-tubulin (cytoskeletal integrity), creatine kinase B (ATP production), and 14-3-3 α/β proteins (signal transduction).
[1] Antioxidant effects restore the balance between pro-oxidative and antioxidative enzyme systems, [1] reducing neuroinflammation through modulation of microglial polarization. The polypeptides cross the blood-brain barrier following intramuscular administration, allowing direct CNS effects [3].
What to expect
Days 1-3
What you might notice
- Polypeptide fractions begin crossing the blood-brain barrier and activating neurotrophic signaling pathways
- Some patients may notice subtle improvements in alertness and concentration
- GABAergic effects may provide mild anxiolytic benefits early in the treatment course
What's normal
- Initial response to Cortexin is beginning at the cellular level
- Different individuals experience Cortexin's onset at different rates
- Transient systemic effects from initial Cortexin exposure are common
What's next
- Maintain consistent Cortexin administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Days 4-10
What you might notice
- Cumulative neuroprotective and nootropic effects develop as the full 10-day treatment course progresses
- Antioxidant balance restoration occurs in brain tissue
- Measurable improvements in cognitive test scores (MMSE, clock drawing test) and reduction in neuronal damage biomarkers (NSE) may become apparent
What's normal
- Cortexin is achieving sufficient receptor engagement
- Initial mechanism of Cortexin is taking effect
- Early transient effects from Cortexin administration are resolving
What's next
- Maintain consistent Cortexin administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Weeks 2-8
What you might notice
- Therapeutic effects continue and may increase after the treatment course ends
- Animal studies demonstrate that memory improvements and hippocampal protection persist for at least 10 days after the last injection
- Clinical benefits in cognitive function and neurological status are maintained during this consolidation period
What's normal
- Cortexin is now achieving steady-state pharmacokinetics
- Measurable changes aligned with Cortexin's mechanism may appear
- Initial adjustment effects typically resolve by this point
What's next
- Maintain Cortexin dosing exactly as established
- Track progress toward intended outcomes in detail
- Review lab work or biomarker changes with your healthcare team
Months 3-6+
What you might notice
- Repeated treatment courses at 3-6 month intervals provide cumulative and sustained benefits
- For chronic conditions such as cerebrovascular disease and cognitive impairment, multiple courses per year are recommended
- Long-term clinical experience in Russia supports the safety and sustained efficacy of repeated course therapy
What's normal
- Full therapeutic effects of Cortexin are well-characterized at this point
- Maintenance of Cortexin's therapeutic effects is typical
- Tolerance patterns with Cortexin are generally stable over months
What's next
- Comprehensive assessment of Cortexin efficacy should be conducted
- Discuss long-term continuation, cycling, or protocol modifications
- Continue regular monitoring of relevant biomarkers or symptoms
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Cortexin over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked about Cortexin
How does Cortexin differ from Cerebrolysin?
Both are brain-derived polypeptide preparations, but they differ in several ways. Cortexin is derived specifically from the cerebral cortex of cattle (and young pigs), [6][7] while Cerebrolysin is derived from whole porcine brain tissue. Cortexin is provided as a lyophilized powder requiring reconstitution and is administered only intramuscularly (up to 10 mg), while Cerebrolysin comes as a ready-to-use solution and can be given both intramuscularly and intravenously in much larger volumes (up to 50 ml). Cortexin is primarily available in Russia and CIS countries from GEROPHARM, [7] while Cerebrolysin (by EVER Pharma, Austria) is approved in over 40 countries. Preclinical studies suggest comparable neuroprotective efficacy between the two preparations [4].
Is Cortexin available outside of Russia?
Cortexin is approved and widely used in Russia and some CIS (Commonwealth of Independent States) countries. [7] It is not approved by the FDA (United States), EMA (European Union), or most other Western regulatory agencies. It may be available through some international online pharmacies, but procurement and use outside approved markets carries regulatory and safety risks. The majority of clinical research on Cortexin has been published in Russian-language medical journals.
Can Cortexin be used in children?
Yes, Cortexin has been used in pediatric neurology in Russia for conditions including cerebral palsy, developmental delays, epilepsy (as adjunctive therapy), and cognitive impairment in children. [7] The pediatric dosage is based on body weight: 5 mg IM daily for children under 20 kg, and 10 mg IM daily for children over 20 kg, given for a 10-day treatment course. [6] Cortexin has demonstrated efficacy and safety as adjunctive therapy in children with cerebral palsy combined with epilepsy in Russian clinical studies [8].
How is Cortexin prepared and administered?
Cortexin is provided as a lyophilized (freeze-dried) white or slightly yellow powder in sealed glass vials. Before use, the powder must be dissolved in 1-2 ml of 0.9% sodium chloride solution (normal saline) or water for injection. [6] The reconstituted solution is then administered by intramuscular injection, typically into the deltoid or gluteal muscle. The injection should be given in the morning to avoid potential sleep disturbance. The reconstituted solution must be used immediately and cannot be stored.
How long do Cortexin effects last after a treatment course?
Animal studies have demonstrated that the neuroprotective and cognitive benefits of Cortexin persist for at least 10 days after the last injection, [4] and clinical experience suggests effects can last for weeks to months. However, for chronic conditions such as cerebrovascular disease and cognitive impairment, repeated treatment courses every 3-6 months [6] are recommended to maintain and build upon therapeutic gains. The multicenter CORNELia study showed sustained cognitive improvements at the 30-day assessment point after treatment initiation [5].
What is the quality of evidence supporting Cortexin?
The evidence base for Cortexin includes multicenter observational studies (such as the CORNELia study with 801 patients), [5] comparative animal studies, [4] and extensive Russian clinical experience. However, it lacks large-scale, randomized, double-blind, placebo-controlled trials published in major international peer-reviewed journals. Most research has been published in Russian medical journals (primarily Zhurnal Nevrologii i Psikhiatrii). While the Russian clinical evidence is substantial, the limited availability of English-language studies and the absence of Western regulatory approval mean that Cortexin's evidence base is not considered strong by international standards.
Further reading
Cortexin history & related research
History · since 1986
Russian brain rescue peptides that cross the blood-brain barrier to restore neural function.
Cortexin is a complex of neuropeptides derived from cattle and pig cerebral cortex. Created in 1986 at the Military Medical Academy in Saint Petersburg, it has been used clinically in Russia and CIS countries since 1999.
Read the full history of CortexinReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Cortexin, on one page.